Topical Therapies

https://www.dermatologytimes.com/view/how-emerging-androgenetic-alopecia-therapies-target-dht-at-the-scalp-level New hair-loss therapies aim to block DHT at follicles, using targeted scalp delivery to reduce systemic side effects and improve male pattern baldness outcomes.

https://www.dermatologytimes.com/view/clascoterone-5-topical-solution-shows-long-term-promise-for-male-pattern-hair-loss Joshua Zeichner, MD, presents phase 3 results showing topical clascoterone 5% stays well tolerated for 12 months and boosts hair density, signaling a new DHT-blocking option.

In this Dermatology Times Expert Perspectives video series, Joshua Zeichner, MD, associate professor of dermatology at Mount Sinai Hospital in New York City, breaks down the key aspects of managing androgenetic alopecia (male pattern hair loss).Zeichner discusses: • Biological Mechanisms: How...